Isotechnika Inc. Appoints Two New Senior Company Officers

Edmonton, Canada (ots/PRNewswire) - Isotechnika Inc. is pleased to
announce that effective October 10, 2007, Mr. Clemens Kaiser will
assume the role of Executive Vice President and Chief Marketing
Officer. This position has been created to focus on
pre-commercialization and commercialization efforts for the Company's
lead drug, ISA247.

Mr. Kaiser comes with extensive experience in the pharmaceutical
industry as he has held numerous executive positions within the Bayer
organization. After joining the Bayer Healthcare Division in 1984, he
held positions with increasing operational responsibilities in the
Philippines, South Africa, Canada, and Greater China. Between 1994
and 1998, Mr. Kaiser was a Member of the Bayer Pharmaceutical
Executive Management Committee and also responsible for Bayer's
Pharmaceutical Business in Asia, Australia, Latin America, Middle
East, Africa and Eastern Europe. During this time, many important
milestones were reached and he became, among other achievements, the
first Chairman of Bayer Healthcare China. Most recently, Mr. Kaiser
was President and CEO of Exatec LLC, a General Electric technology
joint venture. Mr. Kaiser received a degree in Business and Economics
from the Free University in Berlin.

As Chief Marketing Officer, Mr. Kaiser will oversee global
marketing, licensing and business development operations of
Isotechnika. Mr. Kaiser will also be responsible for identifying,
conducting and concluding licensing and partnership discussions and
negotiations for current and future Isotechnika compounds for all
markets. Furthermore, he will be responsible for developing target
product profiles and providing input into clinical programs to
optimize the Company's products in global markets. As a member of the
Senior Management Executive group, he will also provide guidance and
input for Isotechnika's Investor Relations. "With uveitis and
psoriasis already in Phase 3 and transplant about to move into Phase
3, Isotechnika will increase its activities with all partners to
ensure expeditious regulatory approval and launch of ISA247. I am
excited to join Isotechnika at this stage and compliment the team
that has done a terrific job so far," states Mr. Kaiser. "It is
imperative that the Companies' resources are now focused on finding
the shortest way to market so that ISA247 is available to patients
around the world as soon as possible. Preparing for global product
launch in three different indications requires all the team's
attention".

The Company is also pleased to announce the appointment of Dr.
Derrick Freitag to the Senior Management Executive group as Chief
Scientific Officer, effective October 10, 2007. Dr. Freitag's new
role ensures that scientific resources are deployed to optimally
support our drug development programs. Dr. Freitag has worked with
Isotechnika since 1996 and recently held the position of Senior
Director, Biopharmaceutics. In 1994, Dr. Freitag received his Ph.D.
in Pharmaceutical Sciences specializing in drug metabolism from the
University of Alberta. Since joining Isotechnika, Dr. Freitag has
held numerous positions with increasing responsibilities in the
Company's drug metabolism program, the analytical chemistry
laboratory, and the toxicology and drug development programs. Since
2005, Dr. Freitag has been an Adjunct Professor with the Faculty of
Pharmacy and Pharmaceutical Sciences at the University of Alberta in
Edmonton. He has numerous scientifically reviewed journal articles
and abstracts. "My goal is to ensure that our Company's basic science
is translated into optimal patient therapy. By applying basic science
to patient outcomes, we can ensure patient care is at its best by
achieving that fine balance between optimal efficacy and minimal side
effects," states Dr. Freitag.

"My job is to make sure that we are fully prepared to enter the
marketplace with ISA247 and that we have the scientific basis and
recognition to support the market introduction," stated Dr. Robert
Foster, Isotechnika's Chairman & Interim CEO. "From over 10 years of
intensive research and development, we have generated volumes of data
to support our confidence in this important immunosuppressive drug.
ISA247 with its significantly improved safety profile should put us
in good stead relative to other therapies in the transplant,
psoriasis and uveitis marketplaces. Patients, clinicians and
investors should all benefit from our strategy."

About Isotechnika

Edmonton-based Isotechnika Inc. is an international
biopharmaceutical company focused on the discovery and development of
novel immunosuppressive therapeutics that are designed to offer
advantages over other currently available treatments while offering
therapeutic choices to clinicians. Isotechnika looks to become the
market leader of drug therapies for indications such as
transplantation of solid organs (with Hoffman La Roche) and treatment
of autoimmune disorders such as uveitis (with Lux Biosciences) and
psoriasis.

Calcineurin inhibitors are used in the vast majority of all
transplant patients from the time of transplant, continuing for the
entire life of the patient. The market for these drugs currently
exceeds CAD$2 billion annually. Use of the only other two marketed
calcineurin inhibitors, cyclosporin and tacrolimus, while both
efficacious, is associated with various significant safety drawbacks.

Isotechnika's lead drug, ISA247, has successfully completed a
Phase 3 Canadian trial for the treatment of moderate to severe
psoriasis. ISA247 is currently being investigated in a Phase 3
European/Canadian psoriasis trial and a Phase 2b North American trial
for the prevention of kidney graft rejection subsequent to
transplantation. Our partner, Lux Biosciences, is currently
conducting three separate Phase 2/Phase 3 trials investigating ISA247
as a treatment for uveitis.

Isotechnika Inc. is a publicly traded company on the Toronto Stock
Exchange under the symbol "ISA". More information on Isotechnika can
be found at http://www.isotechnika.com.

Partnerships with Isotechnika Inc.
- Hoffman La Roche (April 9, 2002) licensed the worldwide rights to
develop and commercialize ISA247 for all transplant indications.
- Atrium Medical Corporation (September 30, 2005) exclusive worldwide
licensing agreement for use of ISA247 and TAFA93 with drug eluting
devices for non-systemic treatment of vascular, cardiovascular,
target vessel and tissue disorders.
- Cellgate Inc. signed an option agreement (April 25, 2006), granting
an option to obtain an exclusive license to develop and commercialize
patented transporter technology for topical delivery of ISA247 in
patients suffering from mild to moderate psoriasis.
- Lux Biosciences Inc. of Jersey City, New Jersey (May 25, 2006),
Jersey City, New Jersey granted worldwide rights to develop and
commercialize ISA247 for the treatment and prophylaxis of all
ophthalmic diseases.

Forward-Looking Statements

This press release may contain forward-looking statements. Forward
looking statements, including the Company's belief as to the
potential of its products, the Company's expectations regarding the
issuance of additional patents and the Company's ability to protect
its intellectual property, involve known and unknown risks and
uncertainties, which could cause the Company's actual results to
differ materially from those in the forward looking statements. Such
risks and uncertainties include, among others, the availability of
funds and resources to pursue research and development projects, the
ability to economically manufacture its products, the potential of
its products, the success and timely completion of clinical studies
and trials, the Company's ability to successfully commercialize its
products, the ability of the Company to defend its patents from
infringement by third parties, and the risk that the Company's
patents may be subsequently shown to be invalid or infringe the
patents of others. Investors should consult the Company's quarterly
and annual filings with the Canadian commissions for additional
information on risks and uncertainties relating to the
forward-looking statements. Investors are cautioned against placing
undue reliance on forward-looking statements.

ots Originaltext: Isotechnika Inc.
Im Internet recherchierbar: http://www.presseportal.de

Contact:
For further information: Dr. Robert Foster, Chairman & Interim CEO,
Isotechnika Inc., Phone: +1-780-487-1600 (x222), Fax:
+1-780-484-4105, E-mail: rfoster@isotechnika.com; Stephanie
Gillis-Paulgaard, Director, Corporate Communications, Isotechnika
Inc., Phone: +1-780-487-1600 (x243), Fax: +1-780-484-4105, E-mail:
sgillis-paulgaard@isotechnika.com